Table 2. Clinical and biochemical features.
| Groups | Pre-treatment ACHBLF patients (0 day) | Post-treatment ACHBLF patients (28th day) | Healthy controls |
|---|---|---|---|
| Cases | 47 | 47 | 30 |
| Age (year) | 44.48±11.93 | 44.48±11.93 | 40.50±9.24 |
| Sex (male/female) | 37/10 | 37/10 | 16/14 |
| TBIL (mmol/l) | 318.74±118.73*,§ | 146.59±137.35§ | 12.28±4.37 |
| ALT (U/l) | 358.11±249.52*,§ | 62.16±29.83§ | 19.37±7.43 |
| PTA (%) | 34.34±6.74*,§ | 58.65±16.88§ | 106.77±10.28 |
| ALB (g/l) | 32.01±4.35*,§ | 37.01±4.35§ | 42.26±3.46 |
| HBeAg (+/−) | 30/17 | 27/20 | NA |
| HBV DNA (log copies/ml) | 4.09±2.81§ | 3.685±2.43§ | NA |
| MELD score | 19.78±3.88*,§ | 10.61±4.96§ | NA |
| Encephalopathy (0/1/2/3/4) | 18/15/6/5/3 | 23/14/6/3/1 | NA |
| Ascites (0/1/2/3) | 17/17/9/4 | 25/15/5/2 | NA |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; MELD, model for end-stage liver disease; PT, prothrombin time; PTA, prothrombin activity; TBIL: total bilirubin.
Values are expressed as the mean±standard deviation (s.d.) or median (average).
*
P<0.05 for pre-treatment ACHBLF patients vs. post-treatment patients;
§
P<0.05 for ACHBLF patients vs. healthy controls.